Quest Diagnostics (DGX) Tops Q1 EPS by 15c; Raises FY17 EPS Outlook

Go back to Quest Diagnostics (DGX) Tops Q1 EPS by 15c; Raises FY17 EPS Outlook

Quest Diagnostics (DGX) PT Raised to $115 at Canaccord Genuity Following Strong 1Q Report; 'Continues to Prove Skeptics Wrong... Q1 was a Blowout'

April 24, 2017 9:35 AM EDT

Canaccord Genuity raised its price target on Quest Diagnostics (NYSE: DGX) to $115.00 (from $102.00) while maintaining a Buy rating, following the company's first quarter report.

Analyst Mark Massaro notes the company provided one of its best earnings reports in 4 years, delivering first quarter... More

Quest Diagnostics (DGX) PT Raised to $115 at UBS; 'Improved Growth Profile Continues to Build Confidence'

April 24, 2017 9:14 AM EDT

UBS raised its price target on Quest Diagnostics (NYSE: DGX) to $115.00 (from $102.00) while maintaining a Buy rating, following a company update post first quarter results.

Analyst A.J. Rice notes management's strong execution of growth opportunities such as hospital deals that could... More

Quest Diagnostics (DGX) PT Raised to $100 at Barclays Following 1Q Report; Best Headline Growth in 2 Years

April 21, 2017 9:15 AM EDT

Barclays raised its price target on Quest Diagnostics (NYSE: DGX) to $100.00 (from $98.00) while maintaining a Equalweight rating following the company's first quarter earnings.

Analyst Jack Meehan notes the company provided a sizable beat on volume relative to expectations driven by the best headline... More

Quest Diagnostics (DGX) PT Raised to $115 at Deutsche Bank

April 21, 2017 8:26 AM EDT

Deutsche Bank raised its price target on Quest Diagnostics (NYSE: DGX) to $115.00 (from $108.00) while maintaining a Buy rating.

... More

Quest Diagnostics (DGX) PT Raised to $104.50 at Evercore ISI

April 20, 2017 1:03 PM EDT

Evercore ISI raised its price target on Quest Diagnostics (NYSE: DGX) to $104.50 (from $102.00) while maintaining an In Line rating.

Analyst Ross Muken said DGX has become one of the most consistent companies in healthcare. That said, valuation keeps them on the... More